ArticleNeoplasia (New York, N.Y.)2013
CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.
Article in Neoplasia (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 98 citations in OpenAlex.
- Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling.NPJ precision oncology · 2026Article
- Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.Frontiers in immunology · 2026Review
- Advancing osteosarcoma treatment: the impact of intratumoral metabolic reprogramming on immunotherapy.Frontiers in immunology · 2026Review
- Autophagy inhibition in LGALS9-overexpressing nasopharyngeal carcinoma unleashes immune response.Autophagy · 2025Article
- Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.Molecular therapy. Oncology · 2025Article
- Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation.Cellular & molecular immunology · 2025Article
- Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2025Review
- CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens.Frontiers in immunology · 2025Article
- Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.Advances in respiratory medicine · 2024Review
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.Cancer medicine · 2024Review
- Applications of Intravital Imaging in Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2024Review
- Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment.PeerJ · 2024Article
- In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The expanding Pandora's toolbox of CD8Journal of translational medicine · 2023Review
- Host Interactions with Engineered T-cell Micropharmacies.Cancer immunology research · 2023Article
- BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1-driven Immune Phenotypes with Distinct Spatial Orchestration.Molecular cancer research : MCR · 2023Article
- Host-cell Interactions of Engineered T cell Micropharmacies.bioRxiv : the preprint server for biology · 2023Article
- Intravital imaging of the functions of immune cells in the tumor microenvironment during immunotherapy.Frontiers in immunology · 2023Review
- Tumor microenvironment: barrier or opportunity towards effective cancer therapy.Journal of biomedical science · 2022Review
- Spatiotemporal co-dependency between macrophages and exhausted CD8Cancer cell · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy enhances the antitumor adaptive immune T cell response, but the immunosuppressive tumor environment often dominates, resulting in cancer relapse. Antigen-presenting cells such as tumor-associated macrophages (TAMs) and tumor dendritic cells (TuDCs) are the main protagonists of tumor-infiltrating lymphocyte (TIL) immunosuppression. TAMs have been widely investigated and are associated with poor prognosis, but the immunosuppressive activity of TuDCs is less well understood. We performed two-photon imaging of the tumor tissue to examine the spatiotemporal interactions between TILs and TuDCs after chemotherapy. In a strongly immunosuppressive murine tumor model, cyclophosphamide-mediated chemotherapy transiently enhanced the antitumor activity of adoptively transferred ovalbumin-specific CD8(+) T cell receptor transgenic T cells (OTI) but barely affected TuDC compartment within the tumor. Time lapse imaging of living tumor tissue showed that TuDCs are organized as a mesh with dynamic interconnections. Once infiltrated into the tumor parenchyma, OTI T cells make antigen-specific and long-lasting contacts with TuDCs. Extensive analysis of TIL infiltration on histologic section revealed that after chemotherapy the majority of OTI T cells interact with TuDCs and that infiltration is restricted to TuDC-rich areas. We propose that the TuDC network exerts antigen-dependent unproductive retention that trap T cells and limit their antitumor effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.